Three-Drug attack before surgery aims to stop deadly liver Cancer's return
NCT ID NCT04669496
Summary
This study is testing a new three-drug combination given before surgery for a type of aggressive liver cancer called intrahepatic cholangiocarcinoma. The goal is to shrink tumors and lower the very high chance of the cancer coming back after surgery. Researchers will compare this new pre-surgery approach to the current standard of going straight to an operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hospital
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.